within Pharmacolibrary.Drugs.ATC.G;

model G03AA06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.64,
    Cl             = 7.777777777777778e-07,
    adminDuration  = 600,
    adminMass      = 0.3 / 1000000,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>NorgestrelAndEthinylestradiol</td></tr><tr><td>ATC code:</td><td>G03AA06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Norgestrel and ethinylestradiol is a combination oral contraceptive containing a synthetic progestin (norgestrel) and a synthetic estrogen (ethinylestradiol), primarily used for the prevention of pregnancy. This combination is approved and widely used globally for birth control purposes. It may also be used for menstrual regulation in women.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reflect healthy adult female volunteers, typically of reproductive age, after administration of a single oral dose corresponding to a standard tablet (norgestrel 0.3 mg and ethinylestradiol 0.03 mg).</p><h4>References</h4><ol><li><p>Mohamed, MF, et al., &amp; Othman, AA (2019). The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. <i>Journal of clinical pharmacology</i> 59(4) 510–516. DOI:<a href=\"https://doi.org/10.1002/jcph.1350\">10.1002/jcph.1350</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30500075/\">https://pubmed.ncbi.nlm.nih.gov/30500075</a></p></li><li><p>Kuhnz, W (1990). Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women. <i>American journal of obstetrics and gynecology</i> 163(6 Pt 2) 2120–2127. DOI:<a href=\"https://doi.org/10.1016/0002-9378(90)90551-h\">10.1016/0002-9378(90)90551-h</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2124087/\">https://pubmed.ncbi.nlm.nih.gov/2124087</a></p></li><li><p>Olsson, B, &amp; Landgren, BM (2001). The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. <i>Clinical therapeutics</i> 23(11) 1876–1888. DOI:<a href=\"https://doi.org/10.1016/s0149-2918(00)89083-9\">10.1016/s0149-2918(00)89083-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11768839/\">https://pubmed.ncbi.nlm.nih.gov/11768839</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end G03AA06;
